IMS 2023 | Factors to predict PFS in patients with WM treated with BTK inhibitors: iNNOVATE & ASPEN
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, shares insights into studies evaluating the use of BTK inhibitors in Waldenström’s macroglobulinemia (WM), and further discusses factors that may be used to predict progression-free survival (PFS) in these patients. Referencing findings from the iNNOVATE and ASPEN studies (NCT02165397; NCT03053440), Dr Castillo explains that depth of response may not be the best factor to predict rates of PFS in patients treated with BTK inhibitors. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
